spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P Biopharmaceuticals

[Pamplona, 21 October, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medici

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.

The candidate protein selected by Zhittya is human FGF-1, which is a growth factor involved in stimulating new blood vessel growth (angiogenesis) and new neuron growth (neurogenesis). These properties make FGF-1 an excellent therapeutic candidate for treating neurodegenerative diseases,such as Parkinson’s disease, Zhittya’s lead drug development program. Phase I clinical trials are being planned for this indication in the US, Mexico and Europe.

Recent research from several medical centers has indicated that a number of neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), are initiated by vascular dysfunction in the brain leading to defective blood perfusion and loss of neurons in selected regions of the brain.

Due to the stimulating effects of FGF-1 on cell division, it could represent a promising candidate for improving vascular and neuronal regeneration, thereby preventing or improving the devastating symptoms seen in these neurodegenerative diseases. Importantly, this novel therapeutic strategy has the potential to deliver an excellent solution to patients suffering from medical conditions that currently have no cures.

Dámaso Molero, 3P Biopharmaceuticals CEO, explained "it is a pleasure to work with Zhittya and be part of a project whose goal is to obtain a candidate capable of alleviating neurodegenerative diseases through regenerative medicine". In addition, Molero added that "this collaboration demonstrates the experience and knowledge that 3P provides as a partner to develop complex and stimulating projects, even those starting at the tech transfer phase."

Dr. Jack Jacobs, President and Chief Science Officer at Zhittya, explains “we are very pleased to partner with 3P Biopharmaceuticals to produce high quality biological products that can be tested in patients with severe, life-threatening diseases. We look forward to working with 3P on our clinical development projects which hopefully will also include the future commercial production of our drug candidates.”

This partnership once again demonstrates the knowledge and capacity of 3P to carry out process development and manufacturing that is adapted to the needs of each client using mammalian and/or microbial systems. Furthermore, this collaboration supports 3P´s strategic goal to further expand their presence in the US market.

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development, from initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market.

Further information: http://www.3pbio.com/

About Zhittya Regenerative Medicine Inc

Zhittya Regenerative Medicine (Zhittya means “life” in Ukrainian) is advancing a group of drugs which trigger the human body’s natural regeneration processes. Zhittya’s regenerative drugs act by specifically stimulating the growth of new blood vessels (a biological process termed “angiogenesis”) in tissues or organs that have perfusion defects. Lack of blood perfusion to an organ or tissue is the single biggest cause of death in the world. In fact, according to the Angiogenesis Foundation in Cambridge, MA, over 70 human diseases have been linked to a lack of blood perfusion. In addition to its work with Parkinson’s disease, Zhittya has clinical development programs in wound healing and cardiovascular medical conditions, all which are characterized by a lack of blood perfusion.


3P Biopharmaceuticals press contact:

Isabel García Communications and Marketing Responsible at 3P Biopharmaceuticals
Phone: + 34 948 346 480
phone +34 948 34 64 80
web www.3pbio.com/
email Polígono Mocholí, Plaza Cein, 1, 31110 Noáin, Navarra
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>


White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement